Atara Biotherapeutics (ATRA) Return on Equity (2014 - 2026)

Atara Biotherapeutics has reported Return on Equity for 13 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, up 88.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.13% in Q3 2023, with the low at 5.06% in Q1 2024.
• Historically, Return on Equity has averaged 0.3% across 5 years, with a median of 0.01% in 2025.
• Annual changes were most pronounced in 2024 — Return on Equity sank 503 bps — and 2025, when it surged 506 bps.
• Atara Biotherapeutics' Return on Equity stood at 0.01% in 2022, then plunged by 685 bps to 0.11% in 2023, then jumped by 108 bps to 0.01% in 2024, then sank by 100 bps to 0.0% in 2025, then jumped by 85260 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.